The FDA gave thumbs up to Klisyri, developed by Athenex Inc. (ATNX), on December 14, 2020 for the topical treatment of actinic keratosis (AK) on the face or scalp.Actinic keratosis is a pre-cancerous skin lesions caused by years of exposure to the sun.Klisyri (tirbanibulin), a microtubule inhibitor, will be launched in partnership with Almirall during the first quarter of 2021.The drug is under European Medicines Agency review.